secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvalent, Inc. (NUVL)
CIK:        0001861560
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-020806
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvalent reports Q1 2023 net loss of $25.2M; NVL-655 Phase 1 data expected H2 2023
--------------------------------------------------------------------------------

- Net loss of $25.2M ($0.44 per share) for Q1 2023.
- Cash, cash equivalents and marketable securities of $450.5M; runway into H2 2025.
- R&D expenses $22.1M, G&A expenses $8.1M for Q1 2023.
- Preliminary dose-escalation data for NVL-655 (ALK inhibitor) from ALKOVE-1 trial expected H2 2023.
- NVL-520 (ROS1) Phase 1 enrollment ongoing; NVL-330 (HER2) in IND-enabling studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861560/000095017023020806/0000950170-23-020806-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861560/000095017023020806/nuvl-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-020806

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer